Becton, Dickinson and Company (NYSE: BDX), also known as BD, is a leading global medical technology company. It focuses on improving medical discovery, diagnostics, and the delivery of care. The company operates after spinning off its Biosciences and Diagnostic Solutions segments, aiming to be a more focused MedTech firm with key growth platforms.
On August 6, 2026, BD reports its third-quarter fiscal 2026 earnings results. The company announces an earnings per share (EPS) of $3.23. This figure surpasses the Zacks Consensus Estimate of $3.14 per share, representing a positive earnings surprise of 2.87%. This marks the fourth consecutive quarter that BD has outperformed EPS estimates.
Revenue for the period also beats expectations. The company posts revenues of $4.98 billion, which is above the consensus estimate of $4.89 billion by 1.81%. While these results exceed analyst predictions, the earnings of $3.23 are lower than the $3.68 per share from the same quarter last year.
Despite the year-over-year decline, the company shows strong financial health. Year-to-date free cash flow, which is the cash a company generates after accounting for cash outflows to support operations, increases by 44.6% to $1.70 billion. This strong performance leads BD to update its full-year guidance for revenue and adjusted EPS.
The company's current ratio, a measure of its ability to pay short-term debts, stands at a healthy 8.10. As CEO Tom Polen notes, the results show the benefits of a more focused company. The firm continues to advance its growth platforms and strategically allocate capital to drive long-term value.
